W. Abenhardt
Praxis
8 Papers
53 Citations
W. Abenhardt is an academic researcher from Praxis. The author has contributed to research in topics: Capecitabine & Cetuximab. The author has an hindex of 6, co-authored 8 publications.
Chat about Author
Papers
Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer
Hans-Joachim Stemmler,D diGioia,W. Freier,H W Tessen,Gerald Gitsch,W Jonat,W. Brugger,E. Kettner,W. Abenhardt,H Tesch,H J Hurtz,S Rösel,O. Brudler,Volker Heinemann +13 more
TL;DR: Gemcitabine-based chemotherapy appears to be a worthwhile treatment option for pretreated patients with metastatic breast cancer because of comparable results regarding treatment efficacy and toxicity.
Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial.
Sebastian Stintzing,L. Fischer von Weikersthal,Ursula Vehling-Kaiser,Martina Stauch,Holger G. Hass,H. Dietzfelbinger,Daniel Oruzio,S. Klein,Klaus Zellmann,Thomas Decker,M. Schulze,W. Abenhardt,Gerhard Puchtler,Herbert W. Kappauf,Johann Mittermüller,Christopher Haberl,Clemens Giessen,Nicolas Moosmann,Volker Heinemann +18 more
TL;DR: This analysis supports the hypothesis that for the evaluated regimens, a correlation exists between capecitabine-attributed ST and treatment efficacy regarding DCR, PFS, and OS.
27
Prospective multicenter randomized phase III study of weekly versus standard docetaxel (D2) for first-line treatment of metastatic breast cancer.
Hans-Joachim Stemmler,Nadia Harbeck,Isolde Groell de Rivera,Ursula Vehling Kaiser,Gerhard Rauthe,W. Abenhardt,A. Artmann,Harald Sommer,Hans-Gerd Meerpohl,Marion Kiechle,Volker Heinemann +10 more
TL;DR: Severe leukopenia seems avoidable in weekly scheduled single-agent docetaxel and may serve as an important treatment option, particularly in elderly patients and patients with a reduced performance status.
High Efficacy and Low Toxicity of Weekly Docetaxel Given as First-Line Treatment for Metastatic Breast Cancer
J. Stemmler,W. Mair,Martina Stauch,J. Papke,G. Deutsch,W. Abenhardt,B. Dorn,C. Kentenich,M. Malekmohammadi,Christian Jackisch,S. Leinung,O. Brudler,Ursula Vehling-Kaiser,J. Stamp,Volker Heinemann +14 more
TL;DR: The weekly administration of docetaxel is highly efficient and safe as first-line treatment for MBC and may serve as an important treatment option specifically in elderly patients and patients with a reduced performance status.
Prospective Multicenter Randomized Phase III Study of Weekly versus Standard Docetaxel plus Doxorubicin (D4) for First-Line Treatment of Metastatic Breast Cancer.
Hans-Joachim Stemmler,Nadia Harbeck,Isolde Groell de Rivera,Ursula Vehling Kaiser,Gerhard Rauthe,W. Abenhardt,A. Artmann,Harald Sommer,Hans-Gerd Meerpohl,Marion Kiechle,Volker Heinemann +10 more
TL;DR: Given that leukopenia was similar in both arms and the efficacy parameters were at least numerically inferior with the weekly schedule, standard 3-weekly application seems to be preferable for patients requiring combination chemotherapy.